HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levy, R. Articles by Semenkovich, C. F. Search for Related Content PubMed PubMed Citation Articles by Levy, R. Articles by Semenkovich, C. F. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 33, 1005-1015, Copyright © 1992 by Lipid Research, Inc.

ARTICLES

Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy

R Levy, RE Ostlund Jr, G Schonfeld, P Wong and CF Semenkovich
Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.

To better characterize the in vivo effects of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibition on human lipid metabolism, an adolescent male with cholesteryl ester storage disease (CESD) was treated chronically with lovastatin. Therapy was associated with decreased liver-spleen size, improved but not normal serum lipids, a 26% decrease in hepatic cholesteryl ester, a 12% decrease in unesterified hepatic cholesterol, and a fourfold increase in hepatic low density lipoprotein (LDL) receptor protein. Hepatic mRNA levels for the LDL receptor and apolipoprotein (apo) B standardized to levels of hepatic gamma actin mRNA were unchanged with therapy. Kinetic studies revealed no change in the LDL fractional catabolic rate and a decrease in the LDL production rate. Size exclusion chromatography showed striking reductions in plasma very low density lipoprotein (VLDL) cholesterol and intermediate density lipoprotein (LDL) cholesterol but not LDL cholesterol with therapy. Mean LDL particle size and the LDL particle size range were increased by treatment. However, there was no difference in the ability of pretreatment or treatment LDL to bind to the LDL receptor on cultured cells consistent with previous studies in animals, indicating that lovastatin may alter LDL particles to impair interaction with the LDL receptor in vivo but not in vitro. Lovastatin therapy in CESD appears to be clinically beneficial and has complex effects on lipid metabolism that may include a dominant inhibitory effect on hepatic lipoprotein production, posttranscriptionally mediated induction of the LDL receptor, and alterations of LDL particles that interfere with their clearance by the LDL receptor in vivo.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Muntoni, H. Wiebusch, M. Jansen-Rust, S. Rust, U. Seedorf, H. Schulte, K. Berger, H. Funke, and G. Assmann Prevalence of Cholesteryl Ester Storage Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1866 - 1868. [Full Text] [PDF]

				S. M. Dudek and C. F. Semenkovich Essential Amino Acids Regulate Fatty Acid Synthase Expression through an Uncharged Transfer RNA-dependent Mechanism J. Biol. Chem., December 8, 1995; 270(49): 29323 - 29329. [Abstract] [Full Text] [PDF]